CLRB · Cellectar Biosciences, Inc.
Substantial doubt about the company's ability to continue as a going concern.
“These uncertainties raise substantial doubt about the Company's ability to continue as a going concern. The accompanying financial statements have been prepared on the basis that the Company will continue to operate as a going concern, which contemplates it will be able to realize assets and settle liabilities and commitments in the normal course of business for the foreseeable future. Accordingly, the accompanying consolidated financial statements do not include any adjustments that may result from the outcome of these uncertainties.”View the 10-Q filed Aug 13, 2026
Price & Indicators
Raw chart and full-history price indicators begin at the captured split on Jun 24, 2025; bars on opposite sides are not compared.
Up next
Metrics snapshot
Useful current figures from the complete screener profile.
AI Brief
Q2 FY26 earnings call · Aug 13, 2026TL;DR. Cellectar initiated site activation for its confirmatory Phase 3 trial of iopofosine I-131 in Waldenström macroglobulinemia and remains on track to submit an NDA in mid-2027 under the FDA's accelerated approval pathway. The company also presented strong CLOVER WaM data at ASCO (79.2% MRR, 100% clinical benefit rate) and strengthened its balance sheet via an oversubscribed financing providing up to $140 million, though quarterly net loss widened to $6.9 million and R&D spend rose.
- + Initiated site activation for confirmatory Phase 3 of iopofosine I-131 in WM with NDA submission planned mid-2027 under FDA accelerated approval
- + Reported strong CLOVER WaM data at ASCO in patients treated post-BTKi, including 79.2% MRR, 87.5% ORR, 100% clinical benefit rate, and durable responses
- + Completed an oversubscribed financing in May providing up to $140 million, including $35 million up front, strengthening the balance sheet to cash of $34.0 million
- + 12-month CLOVER WaM follow-up showed median duration of response of 17.8 months with VGPR/CR rate rising to 14.5%, reinforcing durability of iopofosine benefit
- − Quarterly net loss widened to $6.9 million from $5.4 million a year earlier
- − R&D expenses nearly doubled year-over-year to $4.6 million as the company ramps Phase 3 and CLR 125 activities
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Strong SellIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
CLRB
this stock
Cellectar Biosciences, Inc.
|
$21.83M | -21.7% | — | — | 1.8% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$130.64B | +13.7% | +46.2% | 30.0 | 1.8% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$80.46B | +1.2% | +20.8% | 19.4 | 2.5% |
|
ARGX
Argenx SE
|
$61.60B | +17.1% | — | — | 2.0% |
|
MRNA
Moderna, Inc.
|
$57.48B | +388.2% | +4.3% | — | 9.8% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionPerformance
Raw-price comparisons begin at the captured split on Jun 24, 2025; windows that need an earlier baseline remain unavailable.
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| CLRB | -1.7% | -6.9% | -28.7% | -8.0% | -21.7% |
| SPY | -1.2% | -1.8% | +17.8% | -0.4% | +12.1% |
| vs SPY | -0.6% | -5.1% | -46.5% | -7.6% | -33.8% |